These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35326587)

  • 1. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.
    Gosain R; Gupta M; Roy AM; Strosberg J; Glaser KM; Iyer R
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
    Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
    Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
    Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
    World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T; Lee L; Jensen RT
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
    Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
    Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
    Marinova M; Mücke M; Mahlberg L; Essler M; Cuhls H; Radbruch L; Conrad R; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):38-46. PubMed ID: 28864881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
    Edfeldt K; Hellman P; Granberg D; Lagergren P; Thiis-Evensen E; Sundin A; Andersson C
    J Neuroendocrinol; 2023 Oct; 35(10):e13342. PubMed ID: 37807573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
    Martini C; Buxbaum S; Rodrigues M; Nilica B; Scarpa L; Holzner B; Virgolini I; Gamper EM
    J Nucl Med; 2018 Oct; 59(10):1566-1573. PubMed ID: 30042164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial.
    Rinke A; Neary MP; Eriksson J; Hunger M; Doan T; Karli D; Arnold R
    Neuroendocrinology; 2019; 109(2):141-151. PubMed ID: 30852564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial).
    Ramage JK; Punia P; Faluyi O; Frilling A; Meyer T; Saharan R; Valle JW
    Neuroendocrinology; 2019; 108(4):317-327. PubMed ID: 30699423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
    Wolin EM; Benson Iii AB
    Oncology; 2019; 96(6):273-289. PubMed ID: 31018209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
    Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
    Eur J Cancer; 2022 Jul; 169():1-9. PubMed ID: 35489301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
    Ronde EM; Heidsma CM; Eskes AM; Schopman JE; Nieveen van Dijkum EJM
    Eur J Cancer Care (Engl); 2021 Nov; 30(6):e13504. PubMed ID: 34462979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
    Blot K; Duchateau L; Lescrauwaet B; Liyanage N; Ray D; Mirakhur B; Vinik AI
    Patient Relat Outcome Meas; 2019; 10():335-343. PubMed ID: 31754316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.